Discover and download resources

files selected

Clear

Home Infusion Overview

Learn about the Home Infusion process and how your patient can receive their migraine treatment at home.

VYEPTI Dosing and Administration Guide

Step-by-step instructions for administering VYEPTI.

Eptinezumab-jjmr: The Purposeful Design

Discover the intentional design features of eptinezumab-jjmr.

VYEPTI Dosing and Administration Video

Step-by-step instructions for the preparation and administration of VYEPTI.

Chanci Patient Testimonial Video

Watch Chanci discuss her experience with migraine and VYEPTI.

PROMISE-1 VYEPTI resource thumbnail

PROMISE-1 Study

Explore the pivotal trial results for eptinezumab-jjmr in episodic migraine.

PROMISE-2 VYEPTI resource thumbnail

PROMISE-2 Study

Explore the pivotal trial results for eptinezumab-jjmr in chronic migraine.

VYEPTI patient support resources thumbnail

Patient Support Resources

See a variety of resources that can help support your VYEPTI patients.

Want updates when more resources become available?

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Full Prescribing Information and Patient Information.